Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K9 | P80192 | 5/20 | 0.67 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.67 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | TEK | Q02763 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250076 | 0.93 | MAP3K9 (0.70) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL2755775 | 0.85 | MAP3K9 (0.64) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL14589768 | 0.83 | MAP3K9 (0.67) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL2755778 | 0.81 | MAP3K9 (1.00) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL3264738 | 0.78 | MAP3K9 (0.68) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL2755760 | 0.77 | MAP3K9 (0.69) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL2755774 | 0.76 | MAP3K9 (0.79) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL2755777 | 0.76 | MAP3K9 (0.68) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL3265885 | 0.74 | MAP3K9 (0.79) | MAP3K9MAP3K11PARP1KDRNTRK1 | |
| SCHEMBL14494184 | 0.74 | MAP3K9 (0.72) | MAP3K9MAP3K11PARP1KDRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-1704148-B1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | MAP3K9 3651/4885MAP3K11 3535/4885PARP1 1033/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | MAP3K9 3651/4885MAP3K11 3535/4885PARP1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.